Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report

Background: Patients with advanced gastric cancer, especially the HER2-positive type, have a poor prognosis; there is a paucity of effective anti-HER2 drug therapies in patients who develop resistance to trastuzumab. Case presentation: We report the case of a 36-year-old male with HER2-positive gast...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Le-Tian, Ma, Jie-Tao, Zhang, Shu-Ling, Li, Xiao-Han, Sun, Li, Jing, Wei, Zhao, Jian-Zhu, Wang, Yan-Ru, Han, Cheng-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951398/
https://www.ncbi.nlm.nih.gov/pubmed/31956604
http://dx.doi.org/10.3389/fonc.2019.01453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951398/
https://www.ncbi.nlm.nih.gov/pubmed/31956604
http://dx.doi.org/10.3389/fonc.2019.01453

Ejemplares similares